Abstract Submission

Abstract Submission

Share your research with the immunodeficiency community

Late-Breaking Abstract Submission is Open!

Key Dates

Abstract Submission Opens Thursday, 04 January-24
Abstract Submission Deadline Tuesday, 07 May 2024 midnight CEST (23:59)
Abstract Submission Extended Deadline Tuesday, 14 May 2024 midnight CEST (23:59)
Abstract Notifications* Mid/End June 2024*
Late-Breaking Abstract Submission Opens Tuesday, 16 July 2024
Late-Breaking Abstract Submission Deadline Wednesday, 14 August 2024

*Note all efforts are made to send notification by the planned date. Should there be any delays with the selection process, a revised date will be posted here.


Please read the submission rules before submitting an abstract.

  • Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
  • Abstracts must be submitted online via the website.
  • Late-breaking Abstracts: may be submitted for oral or poster Viewing.
  • The Scientific Committee will make the final decision as to whether the abstract will be accepted for presentation, with consideration given to the author’s preference.


  • Presenting authors must be registered participants.
  • The same person may serve as presenting author on up to 5 abstracts.
  • Submission of an abstract acknowledges your acceptance for the abstract to be published in the official meeting publications.
  • The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
  • Abstracts that have been previously presented at another meeting may not be submitted.
  • All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication.
  • Only abstracts with results will be accepted for review. Abstracts stating “data will be discussed in the presentation” will NOT be accepted.

Disclosure of Conflicts of Interest

Abstract submitters will be required to disclose any conflict of interest in the submission form.

Publication Embargo

The abstract contents will be available one day prior to the Meeting.


​Before you begin, please prepare the following information:

Presenting author’s contact details:

  • Full first and family name(s)
  • – Email address
  • – Affiliation details: department, institution / hospital, city, country
  • – Phone number

Author and co-authors’ details

Preferred presentation type: oral presentation or poster Viewing.

Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.

Abstract text – limited to 250 words, including references. Do not include tables and figures.

Abstract structure – abstracts should clearly state:

  • Background and aims
  • Methods
  • Results
  • Conclusions

Abstract topic – select the abstract topic per the list of topics.

  • You may enter up to 6 keywords.
  • Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
  • Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
  • Submissions may not contain patient names, hospital ID numbers or other identifying information.
  • Click on the SUBMIT button at the end of the process in order to submit your abstract. You may log in to the system later to make changes to your abstract, up to the submission deadline. After the deadline, changes will not be possible.
  • You will receive an abstract reference number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
  • Please contact us if you have not received confirmation that your abstract has been submitted.
  • Please do not submit multiple copies of the same abstract.


During abstract submission you will be asked to confirm that you agree to the following:

  1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
  2. Submission of the abstract constitutes my consent to publication (e.g. Meeting website, programme, other promotions, etc.)
  3. As the Abstract Submitter, I warrant and represent that I am the sole owner or have the rights of all the information and content (“Content”) provided to the 2024 Meeting of the European Society for Immunodeficiencies and Kenes Group (Hereafter: “The Organisers”). The publication of the abstract does not infringe any third-party rights including, but not limited to, intellectual property rights.
  4. As the Abstract Submitter, I grant the Organisers a royalty-free, perpetual, irrevocable nonexclusive licence to use, reproduce, publish, translate, distribute, and display the content.
  5. The Organisers reserve the right to remove from any publication an abstract that does not comply with the above.
  6. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.


Notification of abstract acceptance or non-acceptance will be emailed to the person listed on the abstract as Presenting author in June 2024.

Abstract-related questions can be directed to: esid_abstracts@kenes.com

   Become a member    Register now    Book Hotel